Optimizing the Use of DMD Therapy in MS Management

Title:

Optimizing the Use of DMD Therapy in MS Management

Topic: Neurology
Relevant Terms: Biomarkers, CIS, Clinically Isolated Syndrome, Disease-modifying Drug Therapy, DMD, Glatiramer Acetate, IFN, Interferon Beta, Interferons, Magnetic Resonance Imaging, MRI, MS, MS Diagnosis, Multiple Sclerosis, Radiologically Isolated Syndrome, RIS
Primary Audience: Neurologists and other health care providers actively involved in the care of patients with multiple sclerosis
Launch Date: 17-Dec-13
Credits: AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Optimizing the Use of DMD Therapy in MS Management

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Select and initiate effective DMD therapies earlier in the course of MS
  2. Develop individualized MS therapies that optimize adherence and improve patient outcomes
  3. Incorporate newer MRI measures and emerging biomarkers to enable more accurate diagnosis and monitoring of disease activity in MS

    Faculty

    Aaron E. Miller, MD
    Professor of Neurology and Medical Director
    Corinne Goldsmith Dickinson Center for Multiple Sclerosis
    Mount Sinai Medical Center
    New York, NY
    Suhayl Dhib-Jalbut, MD
    Professor and Chairman
    Department of Neurology
    RUTGERS-Robert Wood Johnson Medical School
    Chief, Neurology Science
    Robert Wood Johnson University Hospital
    New Brunswick, NJ
    Bruce Cree, MD, PhD, MCR
    Associate Professor of Clinical Neurology
    Clinical Research Director
    Multiple Sclerosis Center
    University of California, San Francisco
    San Francisco, CA
    DISCLOSURE POLICY STATEMENT
    Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
     
    All persons in a position to control the content of a continuing medical education program sponsored by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
     
    The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
     
    Faculty Disclosures
    The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
     
    Bruce Cree, MD, PhD, MCR – Consultant: Biogen Idec, EMD Serono, Genzyme, Novartis, Sanofi-Aventis, Teva Neuroscience; Research: Hoffman La Roche
     
    Suhayl Dhib-Jalbut, MD – Speaker: Bayer HealthCare, Biogen Idec, EMD Serono, Genzyme, Teva
     
    Aaron E. Miller, MD – Consultant: EMD Serono, GlaxoSmithKline, Nuron Biotech, Ono Pharmaceutical, Teva Neuroscience; Consultant/Research: Acorda, Biogen Idec, Genzyme/Sanofi-Aventis, Novartis
     
                                                               
    Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

    Matthew Horn, MD; Blair St. Amand; Jay Katz, MA, CCMEP; Dana Simpler, MD; Joshua Kilbridge: Nothing to disclose
                                                       
     
    DISCLOSURE ATTESTATION
     
    DISCLAIMER
    The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
     
    CREDIT DESIGNATION
     
    Physicians – The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
     
    For questions regarding CME credit, the post-test, or evaluation, please email contact@rockpointe-pcme.com.
     
    ACCREDITATION STATEMENT
    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    HOW TO RECEIVE CREDIT
    By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
     
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 70% or higher on the post-test to receive credit for this activity.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. "
       
    COMMERCIAL SUPPORT

    This program is supported through an educational grant from EMD Seronao, Novartis, and Teva Neuroscience.

    This continuing medical education activity is jointly sponsored by the Potomac Center for Medical Education and Rockpointe.

    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 5.0+ for Mac OSX 10.5 and above
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above